Highlights
Optimized
Screen high-value markers of the tumor immune response.
Flexible
Easily add new markers over time, customizing for your own research needs.
Efficient
Run 24 to 96 samples at a time using the robust Biomark™ HD automated qPCR system.
The Advanta™ IO Gene Expression Assay is a qPCR assay for expression of 170 genes that enables profiling of tumor immunobiology and new biomarker identification.
Designed to meet the rigorous demands of human checkpoint research programs, the Advanta IO Gene Expression Assay includes 91 key markers of tumor immune response that were shown in a multicenter international clinical trial to inform tumor progression and checkpoint therapeutic response1,2. Working with researchers in the biopharmaceutical industry, we further expanded the panel to include 74 additional immuno-oncology markers.
The two-panel set includes genes for identification and functional analysis of immune and cancer cells, including markers found in defined T cell subsets, cytokines and chemokines and markers of immune regulation and immune cell fate. The Advanta IO Gene Expression Assay is a key component of a complete workflow from sample to data supporting your research in tumor immune response.
Panel A
| ARG1 | CLEC4C | IL12A | PDCD1LG2 (PD-L2) |
| BTLA | CSF2 | IL13 | PRF1 |
| CCL2 | CTLA4 | IL17A | PTGER2 |
| CCL22 | CX3CL1 | IL17F | PTGER4 |
| CCL28 | CXCL10 | IL1B | PTGS2 |
| CCR5 | CXCL8 | IL2 | PTPRC |
| CCR7 | CXCL9 | IL2RA | RORC |
| CD1C | CXCR3 | IL4 | SDHA |
| CD244 | EOMES | IL6 | SP2 |
| CD27 | EPCAM | IL7 | TBX21 |
| CD274 (PD-L1) | FOXP3 | IL7R | TGFB1 |
| CD276 | GZMA | ITGAM | TMEM55B |
| CD28 | GZMB | ITGAX | TNF |
| CD3E | HAVCR2 | ITGB2 | TNFRSF14 |
| CD4 | HLA-A | KLRK1 | TNFRSF4 |
| CD40 | HLA-B | LAG3 | TNFRSF9 |
| CD40LG | HLA-C | LGALS9 | TNFSF4 |
| CD48 | HMOX1 | MAP4K1 | TNFSF9 |
| CD69 | ICAM1 | MICA | VCAM1 |
| CD70 | ICOS | MICB | VEGFA |
| CD80 | IDO1 | MS4A1 | VPS33B |
| CD86 | IFNG | NCAM1 | VTCN1 |
| CD8A | IL10 | PDCD1 (PD-1) |
Panel B
| APOBEC3A | CXCR4 | IFNA2 | NKG7 |
| APOBEC3B | CYBB | IGHA1 | NRAS |
| ARG2 | DGAT2 | IGHG1 | NT5E |
| CA4 | EBI3 | IGHM | PYGL |
| CCL18 | ERBB2 | JCHAIN (IGJ) | SLAMF7 |
| CCL21 | FASLG | IGKC | SLAMF8 |
| CCL3 | FCER1G | IGLJ3 | STAT1 |
| CCL4 | FCRLA | IGSF6 | STAT2 |
| CCL5 | FYB | IL10RA | STAT3 |
| CD160 | GATA3 | IL12B | STAT5A |
| CD19 | GNLY | IL15 | STAT5B |
| CD1D | GZMH | IL2RG | STAT6 |
| CD2 | GZMK | IRF9 | TLR7 |
| CD22 | HLA-DMB | ISG15 | TLR8 |
| CD37 | HLA-DPB1 | JAK2 | TNFAIP8 |
| CD52 | HLA-DQB1 | KREMEN1 | TNFRSF18 |
| CD53 | HLA-DRB1 | LAPTM5 | TNFSF18 |
| CD63 | IFI27 | LCK | |
| CTSS | IFIT2 | LRG1 |
Table 1. The Advanta IO Gene Expression Assay gene list by panel. Panel A includes 91 target genes and 5 housekeeping genes. Panel B includes 74 target genes and the same 5 housekeeping genes, along with 17 open assay inlets to facilitate the addition of custom content over time. Refer to Ordering information for the panel content of each component.
Complete workflow from sample to data analysis
Figure 1. Assay workflow. The gene expression assay workflow uses the Juno™ system for IFC preparation and the Biomark HD for qPCR thermal cycling and data acquisition. Generate 175–192 assay results per sample (up to 24 samples) in 4.5 hours with 1.3 hours of hands-on time using the GE 24.192 IFC. Alternatively, generate up to 96 assay results per sample (up to 96 samples) in 6.5 hours with 1.5 hours of hands-on time using the GE 96.96 IFC. After primary data analysis, results can be further analyzed with third-party software, such as GO Immuno-Oncology Workbench.
The Biomark HD advantage
The Advanta IO Gene Expression Assay is optimized to run on the industry-proven Biomark HD system. Leveraging the power of microfluidics, the system uses integrated fluidic circuits (IFCs) to precisely combine multiple reactions at nanoliter volumes. Enabling you to easily automate the gene expression workflow, Biomark HD delivers performance you can trust with minimal hands-on time.
Learn more
Figure 2. Manage sample throughput to meet your research needs with integrated fluidic circuits (IFCs). The Gene Expression 24.192 IFC (left) accommodates up to 24 samples per run. For laboratories with higher throughput needs, the Gene Expression 96.96 IFC (right) accommodates up to 96 samples per run. Respectively, the IFCs generate a total of 4,608 and 9,216 parallel reactions.
|
Replicates per Sample |
Samples per GE 24.192 IFC |
Samples per GE 96.96 IFC |
| 1 | 24 | 96 |
| 2 | 12 | 48 |
| 3 | 8 | 32 |
| 4 | 6 | 24 |
Table 3. Sample capacity per IFC. The number of samples that can be processed in a single run depends on the IFC format and the number of replicates per sample.
Ordering information
| Product Name | Part Number |
| Advanta IO Gene Expression Assay—Panels A & B, GE 24.192, 2 IFCs | 101-7678 |
| Advanta IO Gene Expression Assay—Panel A, GE 96.96, 2 IFCs | 101-6082 |
| Advanta IO Gene Expression Assay—Panel B, GE 96.96, 2 IFCs | 101-6083 |
| Advanta IO Gene Expression Assay—Panels A & B, GE 96.96, 4 IFCs | 101-6084 |
| Recommended Products Sold Separately | Part Number |
| Advanta IO Gene Expression Control 1 | 101-7676 |
| Advanta FFPE RNA Extraction Kit | 101-6773 |
| GO Immuno-Oncology Workbench* | 101-6819 |
Want to learn more?
Provide us with your contact information below.
References
1. Fehrenbacher, L. et al. The Lancet 387 (2016): 1,837–1,846
2. Herbst, R.S. et al. Nature 515 (2014): 563–567
* GO Immuno-Oncology Workbench was developed by GenomOncology.
For Research Use Only. Not for use in diagnostic procedures.